GLP-1 receptor agonists in patients with Type 2 diabetes: cardiorenal protection versus ocular safety [0.03%]
GLP-1受体激动剂在2型糖尿病患者中的应用:心血管肾脏保护与眼部安全性的权衡
Elisabeth Buur Stougaard,Peter Rossing
Elisabeth Buur Stougaard
Beyza Nur Kahraman Kızılcaoluk,Seda Pehlivan
Beyza Nur Kahraman Kızılcaoluk
Luigi Cirillo,Samantha Innocenti,Glenda Cancila et al.
Luigi Cirillo et al.
FINE-ONE, more to come: moving beyond ACEis and ARBs in type 1 diabetes with kidney disease? [0.03%]
FINE-ONE,更多值得期待的内容:1型糖尿病肾病的治疗超越ACEi和ARB?
Marieta Theodorakopoulou,William P Martin,Sebastjan Bevc et al.
Marieta Theodorakopoulou et al.
A life course approach to preventing chronic kidney disease by limiting long-term consequences of early adverse events [0.03%]
从生命历程角度出发,通过限制早期不良事件的长期后果来预防慢性肾脏疾病
Lieke A Hoogenboom,Jeremy Hughes,Victoria A Ilori et al.
Lieke A Hoogenboom et al.
The global epidemic of chronic kidney disease (CKD) is becoming well recognised. Current CKD treatment strategies, however, focus on using drugs to protect kidneys in clinically overt nephropathies together with the optimisation of dialysis...
Daniel Kraus,Razan Sadek,Andreas Kommer et al.
Daniel Kraus et al.
Background and hypothesis: Platelet inhibitor therapy is a relative contraindication to percutaneous kidney biopsies due to concerns about bleeding risk. Here we present an analysis of a prospective observational study on...
Pierre Delanaye,Hans Pottel,Richard J Glassock
Pierre Delanaye
Dried Blood Spot versus i.v. sampling of Iohexol and 99mTc-DTPA for GFR Measurement [0.03%]
血液干片与静脉采血检测碘海醇和99mTc-DTPA测量GFR的研究
Morten B Houlind,Ida K Storgaard,Louise W S Christensen et al.
Morten B Houlind et al.
Background and hypothesis: Iohexol and 99mTc-DTPA are commonly used exogenous filtration markers for determining measured glomerular filtration rate (mGFR). Traditional intravenous sampling is time-consuming and often inc...
Carolin Schneppe,Insa E Emrich,Hans-Joachim Anders et al.
Carolin Schneppe et al.